Drugs / SPL-108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03078400 | Mar 2017 → Jan 2020 | malignant epithelial tumor of ovary | Splash Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPL-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03078400 ↗ |
| Action | Inhibit | “inhibits CD44 mediated induction of multidrug resistance” PMID 35750354 ↗ Aug 2022 |
| Route | Subcutaneous | “Patients were treated with daily and then twice daily SPL-108 subcutaneous injections” PMID 35750354 ↗ Aug 2022 |
| Target | CD44 | “inhibits CD44 mediated induction of multidrug resistance” PMID 35750354 ↗ Aug 2022 |